🎤Brad Haubrich (Touro University Nevada )Neglected and opportunistic infectious diseases affect some of the world’s most vulnerable populations—but often receive the least attention from traditional drug discovery pipelines.In this episode of Concentrating on Chromatography, host David Oliva sits down with Brad Haubrich to explore how early-stage drug discovery is being applied to fungal and parasitic pathogens, including those responsible for neglected tropical diseases and infections that disproportionately affect immunocompromised patients.Brad shares how his lab approaches drug discovery when the pathogen is eukaryotic—and therefore biologically similar to humans—making selectivity one of the biggest challenges. The conversation covers:<ul><li>What defines neglected and opportunistic diseases—and why commercial incentives often fall short</li><li>Target-based vs. phenotypic drug discovery and when each approach makes sense</li><li>Using binding kinetics and residence time to improve selectivity and reduce off-target effects</li><li>Where chromatography, metabolomics, and mass spectrometry still play a critical role—even when not front-and-center</li><li>The growing (and realistic) role of AI in drug discovery, especially for underfunded disease areas</li><li>Why World Neglected Tropical Diseases Day (January 30) matters for raising awareness and accelerating progress</li></ul>This episode highlights how analytical chemistry, separation science, and biological insight intersect in the earliest stages of drug discovery—and why progress in this space depends as much on collaboration and curiosity as it does on technology.<h3>Video Transcription</h3>In this interview, Dr. Brad Haubrich discusses his research focus on neglected tropical diseases (NTDs) and opportunistic infections. His interest in this field originated during graduate and postdoctoral studies, particularly through work on African sleeping sickness. Neglected diseases are defined as conditions that predominantly affect populations in low- and middle-income countries, where both healthcare infrastructure and commercial incentives for drug development are limited. Similarly, opportunistic infections disproportionately impact immunocompromised individuals, including patients with cancer, transplant recipients, and those undergoing immunosuppressive therapy.A key challenge in this area is the limited commercial interest in drug discovery, resulting in fewer therapeutic options despite significant unmet medical needs. The research emphasizes fungal and parasitic pathogens, which present distinct challenges compared to bacterial targets, particularly due to shared biological pathways between pathogens and human hosts.<h4>Drug Discovery Strategies and Challenges</h4>The discussion highlights two complementary approaches used in the lab: target-based and phenotypic drug discovery. Target-based strategies involve identifying and biochemically characterizing specific pathogen proteins, while phenotypic approaches assess compound activity directly in living cells. Each approach has advantages and limitations, particularly in identifying molecular targets and ensuring biological relevance.A major scientific challenge is achieving selectivity. Because eukaryotic pathogens share many proteins with human cells, identifying compounds that selectively inhibit pathogen targets without affecting host systems is difficult. To address this, the lab incorporates binding kinetics as an early screening parameter. Instead of relying solely on traditional potency metrics, this approach evaluates how long a compound interacts with its target, enabling the identification of molecules with prolonged, selective binding (pseudo-irreversible inhibition), which may improve therapeutic specificity.<h4>Role of Analytical Techniques and Chromatography</h4>Although chromatography is not central to all workflows in the lab, it remains critical in several areas. It is widely used by collaborators for compound purification and plays an important role in emerging projects focused on pharmacognosy, where bioactive compounds are isolated from natural sources such as desert flora.Chromatography, coupled with mass spectrometry, is also essential for metabolomics-based target identification. In phenotypic screening, where the molecular target is initially unknown, changes in metabolite profiles can provide insight into biochemical pathways affected by candidate compounds, supporting target deconvolution.<h4>Impact, Training, and Future Directions</h4>The success of research in neglected diseases is not solely measured by commercial outcomes but also by contributions to scientific knowledge and global health. Even incremental findings can support future therapeutic breakthroughs.The interview also emphasizes the role of students, particularly in academic medical settings, where participation in early-stage drug discovery provides valuable insight into the full pipeline from molecular discovery to clinical application.Looking ahead, artificial intelligence (AI) is identified as a key driver of innovation in drug discovery. AI tools can accelerate compound screening, predict bioactivity, and even suggest synthetic pathways. However, their effectiveness in neglected disease research is currently limited by the availability of large, high-quality datasets.<blockquote>This text has been automatically transcribed from a video presentation using AI technology. It may contain inaccuracies and is not guaranteed to be 100% correct.</blockquote><blockquote><h4>Concentrating on Chromatography Podcast</h4>Dive into the frontiers of chromatography, mass spectrometry, and sample preparation with host David Oliva. Each episode features candid conversations with leading researchers, industry innovators, and passionate scientists who are shaping the future of analytical chemistry. From decoding PFAS detection challenges to exploring the latest in AI-assisted liquid chromatography, this show uncovers practical workflows, sustainability breakthroughs, and the real-world impact of separation science. Whether you’re a chromatographer, lab professional, or researcher you'll discover inspiring content!You can find Concentrating on Chromatography Podcast in podcast apps:<ul><li><a target="_blank" rel="noopener noreferrer" href="https://open.spotify.com/show/1wZg67rCjoGju4yhqxI3tL">Spotify</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podcasts.apple.com/tz/podcast/concentrating-on-chromatography/id1788429185">Apple podcast</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podscan.fm/podcasts/concentrating-on-chromatography">podscan</a></li></ul>and on <a target="_blank" rel="noopener noreferrer" href="https://www.youtube.com/@ChromatographyTalk/videos">YouTube channel</a></blockquote>

Drug Discovery Where the Market Doesn’t Go: Targeting Neglected & Opportunistic Pathogens

This study investigates the optimization and functional properties of kombucha enriched with Prunus spinosa juice and bee products (propolis, pollen, and bee bread). Advanced analytical techniques (HPLC–DAD, LC–MS/MS) revealed enhanced phenolic, amino acid, and antioxidant profiles, with bee bread enrichment showing the highest overall bioactive content and sensory acceptance.Propolis-enriched kombucha exhibited the strongest in vitro antidiabetic activity, while pollen enrichment provided the highest amino acid levels. Despite partial losses during digestion, significant retention of bioactives suggests potential postdigestive benefits. These findings highlight the potential of enriched kombucha as a functional beverage with nutraceutical value.<blockquote><h4>The original article</h4><h4><a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acsomega.6c00008">From Chemistry to Functionality: HPLC–DAD/LC–MS/MS Characterization of Bee Product-Enriched Prunus spinosa L. Kombucha with In Vitro Antidiabetic Activity and Bioaccessibility</a></h4>ACS Omega 2026, 11, 8, 14048–14063<a target="_blank" rel="noopener noreferrer" href="https://doi.org/10.1021/acsomega.6c00008">https://doi.org/10.1021/acsomega.6c00008</a><h6>licensed under <a target="_blank" rel="noopener noreferrer" href="https://creativecommons.org/licenses/by/4.0/">CC-BY 4.0</a></h6></blockquote>Selected sections from the article follow. Formats and hyperlinks were adapted from the original.<div>Kombucha tea, a traditionally fermented beverage, is believed to have originated as early as 200–300 BC. In recent decades, it has attracted growing global interest due to its recognized health-promoting properties and its deep cultural roots. <a href="javascript:void(0);">(1,2)</a> Sweetened tea derived from Camellia sinensis is transformed into kombucha through fermentation carried out by a SCOBY (Symbiotic Culture of Bacteria and Yeast), a mixed culture of yeasts and bacteria that forms a cellulose-rich biofilm throughout the process. <a href="javascript:void(0);">(3)</a> SCOBY represents a symbiotic consortium of microorganisms that comprises various yeast genera, including Saccharomyces, Schizosaccharomyces, Zygosaccharomyces, Brettanomyces/Dekkera, and Pichia, as well as both acetic and lactic acid bacteria. <a href="javascript:void(0);">(2)</a> During fermentation, the sugars formed contribute a mild sweetness to the tea, whereas the organic acids synthesized by acetic acid bacteria are responsible for its distinctive sour flavor. <a href="javascript:void(0);">(4)</a> Kombucha tea is traditionally brewed using black tea; however, alternative versions can also be produced with other types of tea. <a href="javascript:void(0);">(5)</a> It has been reported that herbal infusions and fruit juices can also be used for fermentation with the kombucha culture, and due to their chemical composition, these substrates have been shown to serve as promising alternatives. <a href="javascript:void(0);">(6)</a> The antioxidant potential of kombucha tea is primarily linked to its abundant phenolics, with flavonoids playing a significant contributory role. <a href="javascript:void(0);">(7)</a> A high anthocyanin content tends to enhance the antioxidant capacity. <a href="javascript:void(0);">(8)</a> The antioxidant activity of kombucha tea can be improved by incorporating anthocyanin-rich fruits. Accordingly, the use of wild fruits with high anthocyanin content─such as Prunus spinosa L. (blackthorn), Prunus laurocerasus (cherry laurel), and Rubus idaeus (red raspberry)─has been considered a practical way to improve the beverage’s nutritional, functional and sensorial properties. <a href="javascript:void(0);">(9)</a>Propolis is a naturally occurring material that honeybees gather from the resins of different trees and the buds of various plants. <a href="javascript:void(0);">(28,29)</a> Propolis is a chemically complex matrix comprising more than 300 identified components, including flavonoids, phenolic acids, and their ester derivatives, and is associated with a wide range of biological activities such as antiviral, antioxidant, antimicrobial, anti-inflammatory, antitumor, hepatoprotective, and immunomodulatory effects. <a href="javascript:void(0);">(30−34)</a> Minerals and vitamins are also present in high concentrations in propolis. <a href="javascript:void(0);">(28)</a> Bee pollen is formed when bees agglutinate pollen grains using their saliva, nectar, or honey and store them in granular form in their honeycomb cells. The key role of bee pollen is to ensure the colony’s survival by providing the necessary nutrients, thereby supporting development and maintenance processes. <a href="javascript:void(0);">(35)</a> Bee pollen is a natural product rich in bioactive compounds. More than 250 bioactive compounds have been identified in bee pollen derived from different plant species. These basic chemical components include lipids, amino acids, proteins, carbohydrates, fatty acids, phenolic compounds, carotenoids, flavonoids, vitamins, and bioelements. <a href="javascript:void(0);">(36)</a> Exhibits antihyperglycemic, anti-inflammatory, hepatoprotective, nephroprotective, and anticancer properties thanks to its rich and versatile component mixture. <a href="javascript:void(0);">(37,38)</a> Many of these have demonstrated antioxidant, antimicrobial, antidiabetic. They have shown promising results in the treatment of diabetes and obesity, and their potential as natural therapeutic agents has been evaluated. They have been found to increase insulin sensitivity, reduce oxidative stress, regulate appetite, adjust obesity-related hormone levels, and strengthen antioxidant defense systems. <a href="javascript:void(0);">(39,40)</a> The antimicrobial effect of bee bread has been extensively studied. Bakour et al. found that different bacterial species and fungi are sensitive to the hydromethanolic bee bread extract. <a href="javascript:void(0);">(41)</a> A vital bee byproduct, bee bread is formed after the pollen gathered by bees is enriched with nectar and bee saliva, leading to an ensuing lactic acid fermentation process inside the hives. <a href="javascript:void(0);">(42)</a> Bee bread is high in nutrition, with significant carbohydrates, proteins and lipids. It is a rich source of vitamins, phenolic compounds, minerals and essential amino acids, and exhibits multiple chemical activities. <a href="javascript:void(0);">(43,44)</a>The Response Surface Method (RSM) is one of the statistical optimization approaches. This method uses empirical modeling techniques to identify relationships between independent variables and the system response using experimental data. It also allows for determining optimal conditions for achieving the desired outcome by evaluating the effects of process variables on the system response. <a href="javascript:void(0);">(45−47)</a>Previous studies have not extensively investigated the sensory parameters (color, taste, smell, and general acceptance) of kombucha tea enriched with P. spinosa L. and bee products using RSM. The primary aim of this study was to optimize the sensory properties of kombucha formulations enriched with P. spinosa L. and bee-derived ingredients (bee bread, propolis, and pollen) using RSM to determine the most acceptable formulation. While many studies have examined kombucha enriched with various fruit and plant infusions, none have specifically investigated the impact of P. spinosa L. and bee products on kombucha’s sensory and bioactive properties. The study also evaluated the total phenolic content (TPC), total flavonoid content (TFC), antioxidant activity (DPPH•), total anthocyanin content (TAC), phenolic profile (HPLC), microbiological quality, and levels of organic acids amino acids and in vitro bioaccessibility in the developed samples, as well as their antidiabetic activity. RSM-based optimization offers a new methodological approach. It is expected to yield valuable data. This data will improve the functional and disease-fighting properties of kombucha.<h4>2. Materials and Methods</h4><h5>2.9. Analysis of Phenolic Compounds (HPLC)</h5>Chromatographic separation was carried out on an ACE Genix C18 column (250 × 4.6 mm, 5 μm; Agilent), following the procedure reported by Portu et al. (2017). <a href="javascript:void(0);">(56)</a> Phenolics were characterized using an <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=10&amp;search=1260+LC">Agilent 1260 HPLC</a>–DAD system operated under gradient conditions at 30 °C with a flow rate of 0.80 mL/min. The mobile phase comprised solvent A (water supplemented with 0.1% phosphoric acid) and solvent B, applied according to a predefined gradient program. Samples were injected at a volume of 10 μL, and chromatograms were recorded at 280, 320, and 360 nm. Quantitative results were reported as μg/mL.<h5>2.10. Analysis of Organic Acids (HPLC)</h5>HPLC was used to determine organic acid profiles, following a method adapted with minor modifications from Coelho et al. <a href="javascript:void(0);">(57)</a> Organic acids were analyzed using an <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=10&amp;search=1260+LC">Agilent 1260 Infinity LC HPLC system</a> fitted with refractive index (RID) and diode array (DAD) detectors. Samples were filtered through a 0.45 μm syringe filter, and a 20 μL aliquot was injected into an <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=10&amp;search=1260+LC">Agilent Hi-Plex H ion-exchange column</a> (300 × 7.7 mm). Chromatographic separation was carried out using 10.0 mM H2SO4 as the mobile phase at a flow rate of 0.6 mL/min, with the column temperature set to 65 °C and the RID cell maintained at 35 °C. The total run time was 20 min. DAD additionally monitored tartaric, pyruvic, and acetic acids at 210 nm. Quantitative determination was carried out using external calibration standards, and the results were reported in g/L.<h5>2.11. Determination of Free Amino Acids (LC–MS)</h5>Amino acid composition was determined using a method adapted with minor modifications from the procedure described by Bilgin et al. (2019). <a href="javascript:void(0);">(58)</a> A gradient elution scheme involving mobile phases A and B was applied to obtain chromatographic separation at a flow rate of 0.7 mL/min, yielding a total run duration of 7.5 min. Tandem mass spectrometric analyses were performed on an <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=10">Agilent 6460 triple quadrupole LC–MS instrument</a> (Agilent Technologies, Waldbronn, Germany) fitted with an electrospray ionization (ESI) interface. The mass spectrometer was operated with a gas temperature of 150 °C, a gas flow rate of 10 L/min, a nebulizer pressure of 40 psi, and a capillary voltage of +2000 V. All analyses were carried out in triplicate, and the results were reported as mg/100 mL.<h4>3. Results and Discussion</h4><h5>3.4. Phenolic Compounds (HPLC)</h5>As presented in <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acsomega.6c00008#tbl1">Table 1</a>, the total quantified phenolic content differed significantly among the treatments (p &lt; 0.05). The control sample (BKT) exhibited the lowest phenolic concentration (106.35 ± 2.25 μg/mL), whereas pollen supplementation (PL-BKT) resulted in a substantial increase, reaching 159.23 ± 4.82 μg/mL. Further enhancement of the phenolic pool was achieved through propolis (PB-BKT: 178.66 ± 5.04 μg/mL) and bee bread (BB-BKT: 186.15 ± 0.97 μg/mL) supplementation. No statistically significant difference was observed between PB-BKT and BB-BKT in total quantified phenolics; however, both treatments exhibited significantly higher values than PL-BKT and the control, indicating a more pronounced phenolic enrichment.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/ACS_Omega_2026_11_8_14048_14063_Table_1_Changes_in_Total_Phenolic_Compounds_of_Kombucha_Samples_Subjected_to_BKT_PB_BKT_PL_BKT_and_BB_BKT_5a50c7851f.jpg" alt="ACS Omega 2026, 11, 8, 14048–14063: Table 1. Changes in Total Phenolic Compounds of Kombucha Samples Subjected to BKT, PB-BKT, PL-BKT and BB-BKT. Data are presented as mean ± standard deviation (n = 3). Values denoted by different letters within the same row indicate statistically significant differences (p &lt; 0.05). BKT: Blackthorn kombucha tea; PB-BKT: Propolis blackthorn kombucha tea; PL-BKT: Pollen blackthorn kombucha tea; BB-BKT: Bee bread blackthorn kombucha tea. n.d.: could not be detected." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_ACS_Omega_2026_11_8_14048_14063_Table_1_Changes_in_Total_Phenolic_Compounds_of_Kombucha_Samples_Subjected_to_BKT_PB_BKT_PL_BKT_and_BB_BKT_5a50c7851f.jpg 159w," sizes="100vw" width="1054" height="1034">The compound-level distribution suggests that the observed elevation in total phenolics is driven by selective, matrix-dependent enrichment. Bee bread is a functional food thanks to its bioactive compounds and chemical diversity. <a href="javascript:void(0);">(72)</a> The marked increase in chlorogenic acid concentration in BB-BKT, to 79.04 ± 4.66 μg/mL, was a key contributor to the elevated total phenolic content in this group. In contrast, chlorogenic acid remained undetectable or present at negligible levels in the other treatments. Likewise, the enrichment of thermosonicated kiwi juice with bee bread resulted in a statistically significant elevation in chlorogenic acid levels. <a href="javascript:void(0);">(68)</a> The highest catechin hydrate concentration was observed in PL-BKT (121.2 ± 3.36 μg/mL), indicating that pollen supplementation preferentially enhances the flavan-3-ol fraction. In contrast, the markedly elevated levels of quercetin (47.32 ± 2.07 μg/mL) and naringenin (17.59 ± 0.38 μg/mL) detected in PB-BKT support the flavonoid-enriching effect of propolis (p &lt; 0.05). In another study, propolis supplementation of thermosonicated yellow cherry juice was found to increase quercetin content significantly. Additionally, the exclusive emergence of chrysin in the enriched samples, particularly its pronounced accumulation in BB-BKT (66.42 ± 1.84 μg/mL), suggests that bee bread supplementation can substantially reshape the specific phenolic signature of the matrix. This interpretation is further supported by the highest rosmarinic acid level observed in BB-BKT (3.05 ± 0.24 μg/mL). Conversely, the absence of caffeic acid and the flavones fraction across all treatments (n.d.) indicates that the applied interventions exerted limited effects on specific phenolic subclasses.<h5>3.5. Free Amino Acids (LC–MS)</h5>The PL-BKT sample, which was supplemented with pollen, exhibited the highest free amino acid content (see <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acsomega.6c00008#tbl2">Table 2</a>). This outcome differed significantly from all other groups (p &lt; 0.05). Significant increases were observed in proline (47.37 mg/100 mL), leucine (4.10 mg/100 mL), and lysine (4.54 mg/100 mL), indicating that pollen, due to its high protein content, increases amino acid release during fermentation. In contrast, amino acid levels were lower in the sample supplemented with propolis alone (PB-BKT), and some amino acids (e.g., glutamic acid, histidine, threonine) were not statistically different from the BKT sample (p &gt; 0.05).<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/ACS_Omega_2026_11_8_14048_14063_Table_2_Effects_of_BKT_PB_BKT_PL_BKT_and_BB_BKT_on_Free_Amino_Acids_mg_100_m_L_f377c7c7e0.jpg" alt="ACS Omega 2026, 11, 8, 14048–14063: Table 2. Effects of BKT, PB-BKT, PL-BKT and BB-BKT on Free Amino Acids (mg/100 mL). The mean value, along with the standard deviation, is given for the data (n = 3). Values indicated by different letters within the same row differ significantly (p &lt; 0.05). BKT: Blackthorn kombucha tea; PB-BKT: Propolis blackthorn kombucha tea; PL-BKT: Pollen blackthorn kombucha tea; BB-BKT: Bee bread blackthorn kombucha tea." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_ACS_Omega_2026_11_8_14048_14063_Table_2_Effects_of_BKT_PB_BKT_PL_BKT_and_BB_BKT_on_Free_Amino_Acids_mg_100_m_L_f377c7c7e0.jpg 159w," sizes="100vw" width="1055" height="1033"><h4>4. Conclusions</h4>This study demonstrated that kombucha enriched with P. spinosa L. juice and bee products (propolis, pollen, and bee bread) provides a robust model for functional beverage design through RSM-based optimization and advanced analytical characterization (HPLC–DAD, LC–MS/MS). From a sensory perspective, the highest overall acceptability was observed in the bee bread-enriched sample (8.32), which also exhibited the strongest antioxidant response (TPC 257.10 mg GAE/100 mL; TFC 36.16 mg CE/100 mL; DPPH• 57.05 μmol TE/mL). HPLC–DAD data revealed that total phenolics increased to 159.23–186.15 μg/mL following enrichment, and that marker compounds, such as chlorogenic acid and catechin derivatives, varied depending on the formulation. LC–MS/MS supported an increase in free amino acids (particularly proline) with pollen supplementation. Propolis addition highlighted the antidiabetic potential, yielding the highest enzyme inhibition (α-glucosidase: 40.7%; α-amylase: 42.02%). Although a partial reduction in bioactives was observed during in vitro digestion, the preservation of phenolic/flavonoid recovery within approximately the 21–30% range indicates that postdigestive activity may be sustained. Future studies are recommended to expand biomarkers using targeted/untargeted LC–HRMS-based metabolomic approaches, to correlate SCOBY microbiota (16S/ITS) with chemical profiles, and to evaluate shelf life and packaging stability (phenolic degradation kinetics, volatile profile), as well as in vivo/preclinical validation (glycemic response, bioaccessibility). A limitation of this work is that batch-specific botanical origin (palynological) identification of the commercial bee products was not performed; therefore, compositional variability due to botanical source cannot be fully excluded.</div>

From Chemistry to Functionality - HPLC–DAD/LC–MS/MS Characterization of Bee Product-Enriched Prunus spinosa L. Kombucha with In Vitro Antidiabetic Activity and Bioaccessibility

In the week of April 27, the following webinars await you in the field of liquid phase and especially HPLC and LC/MS.<blockquote><h4><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinars">👉 DETAILS AND REGISTRATION IN THE WEBINARS SECTION</a></h4>👉 Search and filter in the largest global database with over 5 500 GC, LC, MS and spectroscopy webinars.</blockquote><h5>1. Separation Science: Analytical Excellence Week 2026: Part 1- Understanding Pharmacopoeia and ACS Compliance</h5><ul><li>Tu, 28.4.2026 09:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6130">Registration</a></li></ul>Discover the critical role of compliant reagents in your lab and learn how to ensure that your analyses meet regulatory standards.<h5>2. Agilent Technologies: PFAS &amp; Our Planet: Environmental Monitoring</h5><ul><li>Tu, 28.4.2026 11:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6140">Registration</a></li></ul>Explore evolving PFAS regulations and practical LC-MS/MS workflows for monitoring PFAS in water, soil, and air, including contamination control, sample prep, and reporting strategies.<h5>3. Restek Corporation: Air Sampling Media Selection and Analysis</h5><ul><li>Tu, 28.4.2026 14:30 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6160">Registration</a></li></ul>This presentation will give an overview of the selection of air sampling media, covering both whole air and sorbent sampling techniques.<h5>4. Tosoh Bioscience: Tosoh Tuesday - What is MALS &amp; When is it Useful?</h5><ul><li>Tu, 28.4.2026 15:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6145">Registration</a></li></ul>Join Tosoh Tuesday to explore MALS fundamentals, practical implementation, and real-world SEC-MALS applications for polymer and biologics characterization.<h5>5. Technology Networks: Mass Spectrometry in Drug Discovery: Covalent and Non-Covalent Screening Applications</h5><ul><li>Tu, 28.4.2026 17:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6114">Registration</a></li></ul>Identifying small-molecule binders for complex biological targets remains a major challenge in early drug discovery.<h5>6. Thermo Fisher Scientific: From Sample to Structure: Crosslinking MS Made Practical - Part 1</h5><ul><li>Tu, 28.4.2026 17:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6115">Registration</a></li></ul>Crosslinking mass spectrometry (XL-MS) is transforming how researchers map protein–protein and protein–nucleic acid interactions.<h5>7. SelectScience: Why researchers turn to reversed phase chromatography when purifying GLP-1</h5><ul><li>Tu, 28.4.2026 17:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6117">Registration</a></li></ul>Purifying synthetic peptides is a critical step in developing advanced biotherapeutics like GLP-1 receptor agonists.<h5>8. Phenomenex: Fundamentals First Bio Series – SEC for Biologics</h5><ul><li>We, 29.4.2026 10:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6149">Registration</a></li></ul>Master SEC fundamentals for biopharma—covering principles, column selection, and troubleshooting with real-world applications in mAbs, AAVs, and nucleic acids.<h5>9. SCIEX: Extending the power of LC-MS/MS: advanced workflows with QTRAP®</h5><ul><li>We, 29.4.2026 10:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6147">Registration</a></li></ul>Discover how QTRAP® workflows enhance LC-MS/MS performance with MS³ selectivity, improving sensitivity, reducing interference, and enabling confident analysis in complex matrices.<h5>10. Metrohm: The Basics of Titration explained</h5><ul><li>We, 29.4.2026 15:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6129">Registration</a></li></ul>In this webinar, Robert Tobler, Senior Application Specialist Titration at Metrohm International Headquarters, will give you an introduction to the basics of titration.<h5>11. Separation Science: Analytical Excellence Week 2026: Part 2 - Benefits of PFAS-Tested Consumables</h5><ul><li>Th, 30.4.2026 09:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6131">Registration</a></li></ul>Gain insights into the importance of PFAS-tested additives and solvents for reliable analysis and their impact on the quality of your results.<h5>12. Evosep Biosystems: Next-Gen HCP Analysis in Biopharma</h5><ul><li>Th, 30.4.2026 16:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6151">Registration</a></li></ul>Discover how LC-MS is advancing biopharma workflows through scalable, high-throughput proteomics.<h5>13. Bruker: Bridging Molecules and Genes: Integrating MALDI Imaging and Spatial Transcriptomics on a Single Tissue Section</h5><ul><li>Th, 30.4.2026 16:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6132">Registration</a></li></ul>Explore how integrating MALDI Imaging with spatial transcriptomics reveals tissue heterogeneity, molecular gradients, and disease-relevant patterns through advanced multimodal workflows.<h5>14. Thermo Fisher Scientific: From Sample to Structure: Crosslinking MS Made Practical - Part 2</h5><ul><li>Th, 30.4.2026 17:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6116">Registration</a></li></ul>Crosslinking mass spectrometry (XL-MS) is transforming how researchers map protein–protein and protein–nucleic acid interactions.

Webinars LabRulezLCMS Week 18/2026

Article

Webinars

Video

Scientists

Food

Scientific article

Interview

Science and research

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

Organomation, founded in 1959, designs and manufactures high-quality nitrogen evaporators and extraction systems. Known for innovation and durability, their lab instruments are used globally for efficient sample preparation with strong customer support.

Organomation

Unchained Labs

Phenomenex

Thermo Fisher Scientific

Restek Corporation

SelectScience

SCIEX

Waters Corporation

The development of peptide drugs necessitates efficient bioanalytical assays for accurate measurement in biologicals. Liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) is preferred technology for its specificity and sensitivity. However, LC-MS/MS assays for peptides such as the high-profile diabetes and weight loss GLP-1 receptor agonist Semaglutide, pose significant method development challenges.In this webinar, we present new data demonstrating a comprehensive and streamlined approach to optimized LC-MS/MS quantification of peptides, addressing the common challenges of efficient sample preparation, MRM selection, non-specific binding, sensitivity and robustness, through the example of the development of an assay for the quantitation of Semaglutide in plasma.<h5>Key Learning Objectives:</h5><ul style="list-style-type:disc;margin-top:0cm;" type="disc" id="isPasted"><li style="line-height:115%;margin-bottom:10.0pt;mso-list:l0 level1 lfo1;tab-stops:list 36.0pt;">Learn step-by-step how to streamline bioanalysis workflows for large peptides such as Semaglutide.</li><li style="line-height:115%;margin-bottom:10.0pt;mso-list:l0 level1 lfo1;tab-stops:list 36.0pt;">Discover practical solutions to common obstacles like non-specific binding and efficient mrm optimisation.</li><li style="line-height:115%;margin-bottom:10.0pt;mso-list:l0 level1 lfo1;tab-stops:list 36.0pt;">Gain insights into boosting sensitivity without compromising the reliability of your bioanalytical methods</li></ul><div><blockquote>Presenter: Samantha Ferries (Senior Applications Chemist, Waters Ltd)Samantha Ferries received her PhD in proteomics from the University of Liverpool in 2018. Since joining Waters in 2018, Samantha has worked on a variety of application areas including Biomedical Research, Pharmaceuticals and Food &amp; Environmental, with a focus on LCMS/MS method development. In 2021 Samantha was part of the team that worked to develop the SARS-CoV-2 LCMS Kit (RUO) to detect &amp; quantify SARS-CoV-2 signature NCAP peptides.</blockquote></div>

Mastering the Quantitative Bioanalysis of Large Peptides and Proteins: A Case Study of GLP-1 Receptor Agonist Semaglutide in Plasma

We present new data demonstrating a comprehensive and streamlined approach to optimized LC-MS/MS quantification of peptides, addressing the common challenges.

A Case Study of GLP-1 Receptor Agonist Semaglutide in Plasma

Ultrashort-chain (USC) per- and polyfluoroalkyl substances (PFAS) are highly polar compounds with carbon chain lengths shorter than C4. Its widespread presence and elevated concentrations in aquatic environments are becoming a major concern, comparable to the well-known issues linked to long-chain PFAS contamination.As such, it is crucial to analyze both USC and long-chain PFAS together in water samples to comprehensively assess and address the full spectrum of PFAS contamination.Join Dr. Shun-Hsin Liang, Senior Principal Scientist of LC Solutions at Restek, as he explores the simultaneous analysis of C1 to C14 perfluoroalkyl carboxylic and sulfonic acids, along with other PFAS types, using two alternative chromatographic approaches, a hybrid HILIC/ion-exchange column and a polar-embedded alkyl phase column. He will also discuss how inert-coated columns can increase sensitivity.Key learning objectives:<ul><li>Learn two viable solutions for the analysis of ultrashort-chain PFAS</li><li>Understand how these solutions can be applied across a range of water matrices</li><li>Discover how inert-coated columns can increase sensitivity</li></ul>Who should attend?Method development specialists, research chemists, and operation scientists interested in PFAS analysis.Certificate of attendanceAll webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.<blockquote>Presenter: Dr. Shun-Hsin Liang (Senior Principal Scientist, LC Solutions, Restek Corporation)Dr. Shun-Hsin Liang is a Senior Principal Scientist at Restek Corporation. He earned his BS and MS degrees from National Taiwan University and completed his Ph.D. study at Michigan State University. Dr. Liang conducted Postdoctoral research in Oncology at the University of Michigan. In 2001, he joined Penn State University as a Research Faculty member, focusing on Molecular Toxicology research. In 2006, Dr. Liang transitioned to MPI Research Inc. as a Senior Research Scientist and played a role as Study Director for GLP analytical projects. In 2013, Dr. Liang joined LC Solutions division of Restek Corporation, specializing in developing application methods across the fields of environmental, food safety, and life sciences.Presenter: Olivia Long (Editorial Team, SelectScience)</blockquote>

Restek Corporation: Incorporating ultrashort-chain compounds into the comprehensive analysis of PFAS

Incorporating ultrashort-chain compounds into the comprehensive analysis of PFAS

Join us to explore the simultaneous analysis of C1 to C14 PFCA and PFSA, along with other PFAS types, using two alternative chromatographic approaches.

Incorporating USC compounds in PFAS analysis

The presentation highlights the advancements and importance of cloud-based data management in the biopharmaceutical industry. Dr. Kristensen discusses how the shift from traditional data handling methods to cloud solutions has revolutionized their workflow, enabling access to vast amounts of data from anywhere, which is crucial given the exponential increase in data generation. He outlines the adoption of native mass spectrometry (MS) techniques since 2018, inspired by advancements seen at NIBA, leading to significant growth in data production.&nbsp;The presentation emphasizes the robustness and reliability of their MS platforms, particularly SEC MS, which has proven effective across multiple instrument generations. Dr. Kristensen underscores the importance of centralized data and metadata retrievability for efficient and accurate analysis. The talk concludes with appreciation for collaborative efforts and the critical role of innovative technologies in driving impactful scientific advancements in oncology and other therapeutic areas.Learning points<ul><li>Cloud-Based Data Management: The transition to cloud-based solutions is essential for handling the exponential increase in data generation.</li><li>Advancements in Mass Spectrometry: The adoption of new mass spectrometry (MS) techniques, such as native MS and SEC MS, has significantly improved the robustness and reliability of analytical platforms.</li><li>Impact of Modifications on Therapeutic Efficacy and Safety: The importance of understanding how various modifications, such as glycation and deamidation, impact the safety and efficacy of biopharmaceutical products.</li></ul>Who should attend?<ul><li>Researchers and Scientists: Those working in glycomics, proteomics, and related fields who are interested in the latest advancements and methodologies.</li><li>Biotechnology and Pharmaceutical Professionals: Professionals involved in the development and commercialization of therapeutics who are looking for ways to accelerate their processes and enhance innovation.</li><li>Academic and Training Institutions: Institutions focused on bioprocessing research and training that can leverage new technologies and approaches to enhance their programs and facilities.</li></ul><blockquote>Presenter:&nbsp; Dr. Dan Bach Kristensen (Principal Scientist, Symphogen)Dan Bach Kristensen holds a Ph.D. in Biology and a Bachelor of Science in Chemistry. Dan is specialized in protein chemistry and mass spectrometry (MS), for which he initially applied in the field of proteome research in Japan and then later in Denmark. For the past 15 years, Dan has been working with analytical development in the biopharmaceutical industry on projects ranging from early discovery through to product registration. Clinical indications include bleeding disorders, neutropenia, autoimmune diseases, and oncology. Dan currently works as a principal scientist at Symphogen, which is specialized in the development of antibodies and antibody mixtures for the treatment of cancer.</blockquote>

Thermo Fisher Scientific: The merger of automated LC fractionation & in-depth characterization

The merger of automated LC fractionation & in-depth characterization

How the shift from traditional data handling methods to cloud solutions has revolutionized their workflow, enabling access to vast amounts of data from anywhere

Automated LC fractionation & in-depth characterization

The presentation showcases the innovative partial T1 digest strategy developed at the University of Sheffield for sequencing mRNA therapeutics. This approach, which utilizes LCMS, enables rapid and efficient sequence validation with over 90% coverage in less than 90 minutes.&nbsp;The technique involves generating overlapping fragments that are visualized through advanced mapping tools, providing clear, color-coded linear maps and spiral plots that indicate sequence coverage and confidence levels. This method has proven particularly valuable for large mRNA molecules, such as self-amplifying RNAs, which can be up to 678,000 nucleotides in length. The collaboration with manufacturing groups exemplifies the practical application of this technology in real-world scenarios, ensuring the integrity and efficacy of mRNA therapeutics. The presentation concludes by highlighting the establishment of a dedicated RNA facility at the University of Sheffield, which aims to further streamline and enhance mRNA analysis and characterization.Learning points<ul><li>Critical Quality Attributes of mRNA: Understanding and monitoring the critical quality attributes (CQAs) of mRNA therapeutics and vaccines are essential.</li><li>Advanced Sequencing Techniques: The use of advanced sequencing methods, such as Sanger sequencing and next-generation sequencing, is crucial for ensuring the correct identity of mRNA sequences.</li><li>Impurity Monitoring and Safety: Monitoring impurities, such as double-stranded RNA and residual DNA from the manufacturing process, is vital for the safety of mRNA therapeutics.</li></ul>Who should attend?<ul><li>Researchers and Scientists: Those working in molecular biology, biochemistry, and pharmaceutical sciences who are interested in the latest techniques for mRNA analysis and characterization.</li><li>Biopharmaceutical Professionals: Professionals involved in the development and production of mRNA-based therapeutics and vaccines, particularly those focusing on quality control and regulatory compliance.</li><li>Analytical Development Teams: Teams dedicated to improving analytical methods for validating the sequence and integrity of mRNA therapeutics.</li></ul><blockquote>Presenter:&nbsp; Prof. Mark Dickman (Professor, University of Sheffield)Prof. Dickman obtained a first-class honours degree in biochemistry/chemistry and his Ph.D. at the Krebs Institute, University of Sheffield. He then joined a biotechnology company, Transgenomic Ltd, and since 2003 has worked in the Dept. of Chemical and Biological Engineering at the University of Sheffield, where his research focuses on the development of analytical methods to characterize biomolecules including mRNA and oligonucleotide therapeutics.</blockquote>

Thermo Fisher Scientific: Characterization and sequence mapping of large RNA and mRNA therapeutics using HRAM

Characterization and sequence mapping of large RNA and mRNA therapeutics using HRAM

The presentation showcases the innovative partial T1 digest strategy developed at the University of Sheffield for sequencing mRNA therapeutics

HRAM for RNA & mRNA therapeutics: characterization, mapping

Ulli Honester, a team leader from Solvias, presented on advancements in mass spectrometry for identifying extractables and leachables (E&amp;L). With over 20 years of experience in proteomics, metabolomics, and small molecule identification, Ulli emphasized that the new state-of-the-art ENL technology is user-friendly and not complex.&nbsp;The presentation highlighted the process of sample preparation and analysis, underscoring the importance of automated peak picking software and high-resolution spectrometers. This technology is crucial for analyzing the thousands of compounds in the human metabolome, aiding in precise identification of markers. The automated systems allow researchers to focus on more critical tasks, enhancing efficiency and patient safety by accurately identifying extractables in drug product formulations. The talk&nbsp;concluded with a discussion on the challenges of peak separation and the reality of dealing with a vast database of compounds, emphasizing the need for advanced software solutions.&nbsp;Learning points&nbsp;<ul><li style="color:#212529;mso-list:l0 level1 lfo1;tab-stops:list 36.0pt;" id="isPasted">Advancements in Mass Spectrometry for E&amp;L Analysis: Attendees will gain insights into the latest state-of-the-art technologies in mass spectrometry that simplify the identification and analysis of extractables and leachables, making the process more user-friendly and efficient.</li><li id="isPasted">Automated Data Processing: The presentation emphasizes the importance of using automated software for peak picking and deconvolution, allowing researchers to focus on critical tasks by reducing the effort required for routine data processing.</li><li>Application of Metabolomics Techniques: By applying techniques learned from metabolomic studies, attendees will understand how to identify significant markers and differences between groups, such as treated versus non-treated samples, enhancing the precision of their analytical studies and contributing to patient safety.</li></ul>Who should attend?&nbsp;<ul><li style="color:#212529;mso-list:l0 level1 lfo1;tab-stops:list 36.0pt;" id="isPasted">Analytical chemists and laboratory scientists specializing in mass spectrometry.</li><li id="isPasted">Pharmaceutical researchers and developers focused on drug formulation and safety.</li><li>Quality control and assurance professionals in the pharmaceutical and biotechnology industries.</li></ul>

Thermo Fisher Scientific: State-of-the-art E&L is not rocket science

State-of-the-art E&L is not rocket science

Ulli Honester, a team leader from Solvias, presented on advancements in mass spectrometry for identifying extractables and leachables (E&L).

Implementation of the recently adopted guideline ICH Q2(R2) on Analytical Procedure Validation can present challenges. In this webinar, Dr. Margareth Marques from the USP will discuss practical guidance around accuracy, precision, limit of quantitation and limit of detection. Then Neil Lander from Waters Corporation will walk us through an Empower CDS tool that enhances the efficiency, accuracy, and compliance of the method validation process. A panel discussion will follow.&nbsp;Key Learning Objectives<ul><li id="isPasted">Address challenges in the implementation of Q2(R2)</li><li>Discover the benefits of the Empower Method Validation Manager</li></ul>Who should attendPharmaceutical testing laboratory scientists and managers, pharmaceutical quality control staff, scientific review staff of regulatory bodies for pharmaceutical products involved with LC procedures and anyone involved in method validation.<blockquote>Presenter: Margareth R. C. Marques, Ph.D. (Sr. Principal Scientist, United States Pharmacopeia)Margareth Marques, Ph.D., is a Sr. principal scientist at the Science Department at the United States Pharmacopeia, Scientific liaison to the USP Expert Committee on Dosage Forms working on general chapters for performance tests (dissolution/drug release), and for some pharmaceutical dosage forms (products applied to the skin, ophthalmic products, etc.), also responsible for the USP general chapters on osmolality, method validation and method transfer. Dr. Marques is also responsible for developing specifications for reagents, test solutions, buffer solutions, etc., used in USP – NF monographs. She manages the USP database on chromatographic columns, the USP database on dissolution methods and the USP web site on column equivalency. She has a B.Sc. and an M. Sc. both in Pharmacy by the University of Sao Paulo, Brazil. She has a Ph. D. in Analytical Chemistry by the State University of Campinas, Brazil. She managed analytical laboratories at Ciba-Geigy, Sandoz, and Astra.Presenter: Neil Lander (Principal Product Manager - Informatics Group, Waters Corporation)Neil has worked for Waters Corporation since 1994 and has held a variety of positions including Technical Support Specialist, Technical Trainer, Manager Customer Education and currently, Principal Marketing Manager in Waters in the Informatics group. Neil provides internal support for Empower CDS software and is focused on developing laboratory software solutions that help organizations achieve their scientific and operational objectives. Prior to joining Waters Corporation, he was an analytical chemist where he gained experience in both the cosmetics and specialty chemical industries.Presenter: Moderated by: Isabelle Vu Trieu (Pharmaceutical Market Development Manager, Americas, Waters Corporation)Isabelle is a business development professional dedicated to delivering benefits to analytical scientists in the life sciences industry. With over 20 years of experience in providing chromatography and mass spectrometry solutions, Isabelle is particularly interested in helping pharmaceutical scientists achieve the data quality and integrity needed to drive decisions for drug quality, safety and efficacy. Isabelle joined Waters in 2009 and currently manages the development of the pharmaceutical market in the Americas. She holds Masters’ degrees in Chemistry from Columbia University and the University Claude Bernard in Lyon, France as well as a Chemical Engineering degree from Ecole Supérieure de Chimie Physique Electronique in Lyon, France.</blockquote>

Waters Corporation: Solving Problems That Matter - a Waters webinar series featuring USP speakers

Method Validation

We´ll discuss practical guidance around accuracy, precision, limit of quantitation and limit of detection and next we´ll walk you through an Empower CDS tool.

Episode 12: Method Validation

<div id="zephr-body-wall"><div>Development and production of IVT mRNA vaccines require measurements of Critical Quality Attributes (CQAs), such as identity, purity, quality, and quantity. Orthogonal methods developed for such purposes are outlined in the USP guidelines for mRNA vaccines.Agilent Technologies provides many analytical solutions that are used by leading pharmaceutical companies in early-stage drug development through production quality control (QC) and final product release. These systems help users save time and money with optimized workflows, streamlined processes, and fast time-to-results.Whitney Pike, M.Sc, Application Scientist and Dr. Sonja Schneider, Manager, Application Development, Agilent Technologies, will discuss how automated electrophoresis and LC/MS systems solutions from Agilent provide reliable insights for IVT mRNA workflows at many steps, from QC of the initial plasmid DNA, throughout the IVT process, to the finished mRNA drug product.Key learning objectives<ul><li>Explore QC throughout the entire IVT mRNA workflow, including data from various nucleic acids and LNP analyses</li><li>Discover how Agilent instruments/technologies, such as the Fragment Analyzer and LC/MS systems, can be used for different CQAs</li><li>Learn how Agilent is working together with its partners to provide reliable insights for all aspects of the IVT mRNA workflow</li></ul>Who should attend?<ul><li>Researchers, lab managers, lab directors, QA/QC managers performing IVT mRNA analysis in biotherapeutics research and production</li></ul>Certificate of attendance All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.For Research Use Only. Not for use in diagnostic procedures. PR7001-2498<blockquote>Presenter: Whitney Pike, MA (Application Scientist, Agilent Technologies)Whitney joined Agilent in 2016 and is an Application Scientist with a focus on the Agilent Automated Electrophoresis instruments. She played a pivotal role in the release of the Femto Pulse system as a scientist on the product development team. She completed her master’s degree in biology, with an emphasis on cellular, molecular, and developmental biology, before working at a core facility, responsible for performing next-generation sequencing studies.Presenter:&nbsp;Dr. Sonja Schneider (Dr. Sonja Schneider, Manager, Application Development, Agilent Technologies)Dr. Sonja Schneider completed her diploma degree in biology and her PhD in biochemistry before joining Agilent in 2011 as an Application Scientist for biopharma applications. She progressed into her current role as Manager, of the Application Development Team in 2016, whilst simultaneously working in the laboratory on up-to-date biopharma applications.Presenter:&nbsp;Olivia Long (Olivia Long, Editorial Team, SelectScience) (moderator)</blockquote></div></div>

Select Science: From Start to Finish: How Agilent Can Support Better Decisions in IVT mRNA-Based Biopharmaceutical Analysis

From Start to Finish: How Agilent Can Support Better Decisions in IVT mRNA-Based Biopharmaceutical Analysis

We will discuss how automated electrophoresis and LC/MS systems solutions from Agilent provide reliable insights for IVT mRNA workflows at many steps.

Agilent's Support in IVT mRNA Biopharmaceutical Analysis

Overview<ul><li>General troubleshooting approach</li><li>HPLC troubleshooting steps and diagnosing tips</li><li>Preventive maintenance and column care</li></ul>Key Learning Points<ul><li>Understand systematic elimination as the best approach for troubleshooting</li><li>Learn the steps to identify and solve chromatographic problems</li><li>Discover column CQA as a tool to help identifying if it’s a system or column related issues</li><li>Know the benefit of filtration and using a guard</li></ul>Who Should AttendAny scientists who would like to gain more knowledge on HPLC troubleshooting or anyone who is experiencing challenges with identifying, solving and avoiding HPLC issues.<blockquote>Presenter: Grace Guo (Senior Technical Specialist, Phenomenex)Grace Guo graduated from the Johns Hopkins University with a Master’s degree in Material Science and Engineering. She joined Phenomenex Technical Team in 2017 providing technical support globally. With more than 9 years of experience on SPE, HPLC and GC, she delivered 80+ seminars and webinars globally covering food and environmental, clinical, pharma and biopharma industry.</blockquote>

Phenomenex: LC Troubleshooting Quick Guide: Spot Problems Fast & Fix Them Like a Pro!

LC Troubleshooting Quick Guide: Spot Problems Fast & Fix Them Like a Pro!

In this webinar - General troubleshooting approach, HPLC troubleshooting steps and diagnosing tips and preventive maintenance and column care.

LC Troubleshooting Quick Guide: Spot Problems Fast & Fix 

We invite you to join our webinar on nitrosamine and NDSRIs, specifically examining their analysis and implications in the pharmaceutical industry. Nitrosamines, a group of potentially carcinogenic impurities, have gained considerable attention in recent years because of their presence in certain drug substances. It is essential to understand their analytical characteristics to ensure patient safety and adhere to regulatory guidelines. Let’s delve into the world of pharmaceutical analysis together!Discussion points:<ul><li>Understanding nitrosamines and NDSRIs: an overview</li><li>Analytical techniques for detection and quantification</li><li>Regulatory landscape and compliance</li><li>Real case studies of drug substances</li><li>Column selection for nitrosamines analysis</li></ul>

SCIEX: Unlocking precision: nitrosamine and NDSRI analysis 

Unlocking precision: nitrosamine and NDSRI analysis 

We invite you to join our webinar on nitrosamine and NDSRIs, specifically examining their analysis and implications in the pharmaceutical industry.

Testing stability of your proteins and formulations can feel like being buried alive when screening boat loads of candidates and conditions. Most classic tools are either inflexible, one-hit wonders that don’t give the full stability picture or seriously low-throughput, creating major bottlenecks that eat up valuable time you need for everything else you’ve got to get done, like yesterday.Aunty is the fastest and highest throughput protein stability characterization tool on the planet. Load up to 96 of your samples into its plate and Aunty will power through piles of thermal melting and aggregation experiments at unmatched speeds - reading fluorescence, SLS and DLS of the whole plate every minute of a thermal ramp. Screen gobs of candidates and conditions with as many replicates as you want. Aunty busts out plates of results with unprecedented speed and data resolution.Join this webinar to see how to set up and run an Aunty experiment. Get a walk-through of Aunty’s data analysis of &nbsp;Tm &amp; Tagg and colloidal stability experiments and get a peek at the highest resolution stability data you’ve ever seen.<blockquote>Presenter: Andre Mueller, PhD (Marketing Manager, Biologic Solutions, Unchained Labs)Andre Mueller, PhD, is the Product Manager for Aunty and Honeybun at Unchained Labs, where he supports the development of biologic and gene therapy drugs. He specializes in fluorescence, static and dynamic light scattering, focusing on biophysical characterization of proteins and viral vectors. His research background spans from structural biology to plant physiology, with experience in labs across Germany, Sweden, Denmark, and the USA. Andre earned his PhD at the Carlsberg Laboratory and completed a postdoctoral fellowship at Stanford University.Moderator: Ross Walton, PhD (Sr. Applications Scientist, Unchained Labs)</blockquote>

Unchained Labs: Meet Aunty, the Queen of high-throughput protein stability characterization

Related content

Webinars LabRulezLCMS Week 18/2026

From Chemistry to Functionality - HPLC–DAD/LC–MS/MS Characterization of Bee Product-Enriched Prunus spinosa L. Kombucha with In Vitro Antidiabetic Activity and Bioaccessibility

Drug Discovery Where the Market Doesn’t Go: Targeting Neglected & Opportunistic Pathogens